EVLO (Evelo Biosciences) ROE % Adjusted to Book Value: 0.00% (As of Sep. 2023)


What is Evelo Biosciences ROE % Adjusted to Book Value?

Evelo Biosciences EVLO -99.00% ROE % Adjusted to Book Value is 0.00% as of Sep. 2023.

Evelo Biosciences's ROE % for the quarter that ended in Sep. 2023 was 0.00%. Evelo Biosciences's PB Ratio for the quarter that ended in Sep. 2023 was N/A. Evelo Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 was N/A.

Evelo Biosciences ROE % Adjusted to Book Value Related Terms

Evelo Biosciences ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Evelo Biosciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evelo Biosciences ROE % Adjusted to Book Value Chart

Evelo Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -22.73 -39.96 -10.97 -16.63 0.00

Evelo Biosciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.38 0.00 0.00 0.00 0.00

EVLO vs IMNN, EDSA, TMBR: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Evelo Biosciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evelo Biosciences ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evelo Biosciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Evelo Biosciences's ROE % Adjusted to Book Value falls into.


Evelo Biosciences ROE % Adjusted to Book Value Calculation

Evelo Biosciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-6,232.76% / N/A
=N/A

Evelo Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Evelo Biosciences (EVLO) has a ROE % Adjusted to Book Value of 0.00% as of Sep. 2023. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Evelo Biosciences and its competitors.
Is Evelo Biosciences' ROE % Adjusted to Book Value too high?
Evelo Biosciences' current ROE % Adjusted to Book Value is 0.00%.
How does Evelo Biosciences' ROE % Adjusted to Book Value compare to IMNN and EDSA?
Evelo Biosciences' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Evelo Biosciences and its competitors. Evelo Biosciences's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evelo Biosciences stock overvalued right now?
Evelo Biosciences (EVLO) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Evelo Biosciences (EVLO), the current ROE % Adjusted to Book Value is 0.00% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evelo Biosciences Business Description

Address 620 Memorial Drive, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.